INTUITIVE SURGICAL INC
For the period ended Sep 30, 2025. Filed Oct 22, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 22, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Plans
On July 29, 2025, Myriam J. Curet, M.D., F.A.C.S., the Company’s Chief Medical Officer, adopted a Rule 10b5-1 trading plan. Dr. Curet’s trading plan provides for the potential sale of up to 24,003 shares of the Company’s common stock, including the potential exercise and sale of up to 9,131 shares of the Company’s common stock subject to stock options, until July 29, 2026. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.
On September 12, 2025, Mark P. Brosius, the Company’s Chief Manufacturing and Supply Chain Officer, adopted a Rule 10b5-1 trading plan. Mr. Brosius’s trading plan provides for the potential sale of up to 19,730 shares of the Company’s common stock, including the potential exercise and sale of up to 9,000 shares of the Company’s common stock subject to stock options, until February 14, 2027. This trading plan was entered into during an open insider trading window and is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and the Company’s policies regarding transactions in the Company’s securities.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.